Table 2

Characteristics of the trials

Study characteristicsCategoriesDescription
Nature of ADGroup Sequential Design (GSD) / Sample Size Re-estimation (SSR) / Dose Selection (DS)/ Dose Escalation (DE) / Seamless / Interim AnalysisThe type of AD used in the trial.
Stopping ruleFutility/Efficacy/Two sided/N/AIf a stopping rule was used, what was the nature of the stopping rule.
Year of study completionNoneThe year of study completion.
Population under studyNoneA description of the population studied for example, patients with diabetes.
Chronicity of RRTAKI/ESKDA category for the chronicity of RRT, either AKI or ESRD.
InterventionNoneA free-text description of the intervention.
Nature of the interventionMedication/Medical Device/Dialysis ParameterA category for the nature of the intervention.
Primary outcomeNoneA description of the primary outcome of the trial.
Type of primary outcomeContinuous or dichotomousA categorial variable for the type of primary outcome variable.
Nature of primary outcomeSurrogate, patient-centred or hard clinicalA categorial variable for the nature of primary outcome variable either surrogate, patient-centred or hard clinical.
Dialysis modalityHaemodialysis, peritoneal dialysis, haemodiafiltration or haemofiltrationA categorial variable for the dialysis modality.
Sample size of studyNoneThe number of participants in the study.
The country of the lead investigatorNoneThe country of the lead investigator.
The funder of the studyPublic/PrivateA categorial variable for source of funding for the study.
Study phasePhase II/Phase III/Combined Phase II/IIIA categorial variable for study phase.
  • AD, adaptive design; AKI, acute kidney injury; ESKD, end-stage kidney disease; ESRD, end-stage renal disease; RRT, renal replacement therapy.